Clinical Trial Update: Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating neurosurgical resection followed by intraoperative radiotherapy using the Xoft Axxent eBx System in combination with bevaciz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Xoft Axxent eBx System

Snippet

Sponsor: Xoft, Inc. | Conditions: Glioblastoma, Recurrent Glioblastoma | Phase 2 | Status: TERMINATED